EAM
TBPH icon

Exos Asset Management’s Theravance Biopharma TBPH Stock Holding History

Exos Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,796
Closed -$26K – 681
2021
Q2 		$26K Buy
+1,796
New +$33.7K 0.01% 673

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Exos Asset Management's TBPH Position: Q3 2021 in Review

Exos Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 1,796 shares — an estimated $26K sold.

Exos Asset Management first reported a position in TBPH in Q2 2021 and held it in 1 quarter. The position peaked at $26K in Q2 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • Exos Asset Management reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • Exos Asset Management sold 1,796 Theravance Biopharma shares in Q3 2021, an estimated $26K.
  • Exos Asset Management first reported a position in Theravance Biopharma in Q2 2021 and held it in 1 quarter.
  • Exos Asset Management's Theravance Biopharma position peaked at $26K in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.